Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Study backs rapid test for "super bugs":

This article was originally published in Clinica

Executive Summary

Canadian firm ID Biomedical will file in February for FDA-clearance to market its rapid test for methicillin-resistant Staphylococcus aureus (MRSA) after receiving promising preliminary results in US clinical trials. The test for the potentially fatal so-called "superbugs", which are becoming increasingly prevalent in hospitals, was shown to have an accuracy of 100% in an analysis of 308 samples. The Velogene Rapid MRSA test, which is based on the Vancouver, British Columbia company's Cycling Probe Technology, detects the mecA gene responsible for antibiotic resistance.

You may also be interested in...



The Race To Develop A COVID-19 Vaccine: mRNA Pioneers Lead The Way

Our updated graphic tracker of key developments from the leading vaccine candidates.

Artios Pharma Nears Clinic With DNA Repair Response Anticancers

The UK’s Artios has linked up with Merck KGaA in a potentially multi-billion dollar deal to collaborate on discovering and developing up to eight oncology drug targets associated with DNA damage response processes, and is also progressing its own lead compounds through its pipeline.

Fauci Apologizes For UK V US Comments: Not Better, Not Worse, Just Different

The UK’s rapid authorization of the Pfizer/BioNTech COVID-19 vaccine has sparked a public debate over regulatory processes at some of the world’s key regulatory bodies.

Topics

UsernamePublicRestriction

Register

OM016204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel